Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis
Clinics and Practice · 20.03.2023 · 13 (2) · 454-469
DOI: 10.3390/clinpract13020041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics and Practice, online erschienen am 20.03.2023. Verfasst von Kajol Kumari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Department, Ghulam Muhammad Mahar Medical College, Sukkur 65200, Pakistan. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Testosterone replacement therapy (TRT) has been used to treat hypogonadal males with type 2 diabetes mellitus (T2DM) for a long time, despite variable results. This meta-analysis examines TRT’s role in hypogonadal males with T2DM. The databases PubMed, Embase, and Google Scholar were searched for relevant RCTs and observational studies. Estimated pooled mean differences (MDs) and relative risks with 95% confidence intervals were used to measure the effects of TRT (CIs). When compared to the placebo, TRT improves glycemic management by significantly reducing glycated hemoglobin (HBA1c) levels (WMD = −0.29 [−0.57, −0.02] p = 0.04; I2 = 89.8%). Additionally, it reduces the homeostatic model assessment levels of insulin resistance (WMD = −1.47 [−3.14, 0.19]; p = 0.08; I2 = 56.3%), fasting glucose (WMD = −0.30 [−0.75, 0.15]; p = 0.19; I2 = 84.4%), and fasting insulin (WMD = −2.95 [−8.64, 2.74]; however, these results are non-significant. On the other hand, HBA1c levels are significantly reduced with TRT; in addition, total testosterone levels significantly increase with testosterone replacement therapy (WMD = 4.51 [2.40, 6.61] p = 0.0001; I2 = 96.3%). Based on our results, we hypothesize that TRT can improve glycemic control and hormone levels, as well as lower total cholesterol, triglyceride, and LDL cholesterol levels while raising HDL cholesterol in hypogonadal type 2 diabetes patients. To this end, we recommend TRT for these patients in addition to standard diabetes care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicine Department, Ghulam Muhammad Mahar Medical College, Sukkur 65200, Pakistan.
- Medicine Department, Jinnah Sindh Medical University, Karachi 75510, Pakistan.
- Medicine Department, Dow University of Health Sciences, Karachi 74200, Pakistan.
- Medicine Department, Karachi Medical and Dental College, Karachi 74700, Pakistan.
- Medicine Department, King Edward Medical University, Lahore 54000, Pakistan.
- Medicine Department, Punjab Medical College, Faisalabad 38000, Pakistan.
ORCID-Profile: Kajol Kumari, Muhammad Shehryar, Mahima Khatri, Satesh Kumar, Ajay Kumar
Zitieren
APA
Kumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., Kumar, S., & Kumar, A. (2023). Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis. Clinics and Practice, 13(2), 454-469. https://doi.org/10.3390/clinpract13020041
Vancouver
Kumari K, Kumar R, Memon A, Kumari B, Tehrim M, Kumari P, et al. Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis. Clinics and Practice. 2023;13(2):454-469. doi:10.3390/clinpract13020041
BibTeX
@article{Kumari2023,
author = {Kumari, Kajol and Kumar, Rohan and Memon, Areeba and Kumari, Beena and Tehrim, Moniba and Kumari, Pooja and Shehryar, Muhammad and Islam, Hamza and Islam, Rabia and Khatri, Mahima and Kumar, Satesh and Kumar, Ajay},
title = {Treatment with Testosterone Therapy in Type 2 Diabetic Hypogonadal Adult Males: A Systematic Review and Meta-Analysis},
journal = {Clinics and Practice},
year = {2023},
volume = {13},
number = {2},
pages = {454--469},
doi = {10.3390/clinpract13020041}
}
EUVIMED